Understanding the migration of cancer cells

June 23, 2008

Activity of regulatory proteins for the growth of filopodia and lamelopodia clarified
Lamellipodia are veil-shaped protrusions of the plasma membrane, that can turn into upward-curled ruffles if they fail to adhere to the substrate. A dendritic meshwork of short and highly branched actin filaments might constitute their main structural component. The other type of protrusion, the filopodia, are finger-like and consist of parallel, long and unbranched actin filaments. Interestingly, fast-crawling cells mainly form lamellipodia/ruffles while poorly migrating or non-motile cells often show the coexistence of both lamellipodial and filopodial protrusions. These observations suggest that the lamellipodia-to-filopodia selection might regulate cell migration. Moreover, the pivotal contribution of lamellipodial and filopodial protrusions to important developmental and homeostatic processes certainly requires tight regulatory mechanisms.

Unfortunately, while the microscopic morphology, dynamic development and protein signature of both lamellipodia/ruffles and filopodia have been investigated, little is known about the mechanisms whereby cells co-ordinate these actin-based extensions. Therefore, we urgently need to better understand this basic process to ultimately increase our therapeutic intervention arsenal against the metastatic progression of cancers.

It is known that the activity of regulatory proteins for the growth of the actin cytoskeleton Arp2/3 complex along with WAVE and mDia2 produce a burst of actin polymerization required for the formation of lamellipodia/ruffles and filopodia, respectively. In the forthcoming issue of Nature Cell Biology Metello Innocenti and coworkers report that, starting from the unexpected observation that mDia2, WAVE and Arp2/3 form a complex, they discovered how filopodia extensions are generated and integrated with lamellipodia/ruffles in human cancer cells. At the molecular level, WAVE and Arp2/3 jointly promote lamellipodia/ruffles outgrowth and cell migration and at the same time inhibit mDia2-dependent filopodia formation. Moreover, emission of filopodia occurs only after the disassembly of the mDia2-WAVE-Arp2/3 complex. Thus, it is likely that suppression of filopodia by the ruffling-making machinery is needed for cancer cells to move efficiently.

Their results pave the way to a cogent molecular analysis of the interplay between lamellipodia/ruffles and filopodia in regulating both the migratory and invasive abilities of cancer cells. The researchers anticipate that new and more specific therapies to counteract cancer will be developed exploiting these exciting findings.


Source: Goethe University Frankfurt

Related Stories

Recommended for you

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.